SavedAdd your journal

Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 2

Denatüre edici yüksek performanslı likit kromotografi yöntemi ile ABL geni kinaz bölgesi mutasyonlarının taranması

ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method

YÜCEL ERBİLGİN
Suzin ÇATAL
AHMET EMRE EŞKAZAN
ÖZDEN HATIRNAZ NG
Teoman SOYSAL
UĞUR ÖZBEK
Pages
97–102
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Analyzing the mutations and monitor- ing (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become a valuable tool for regular testing of patients in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor imatinib, the development of resistance against imatinib has been observed.
📊
Key Findings & Data:This study describes the use of denaturing high performance liquid chromatography (dHPLC) as a method to screen for muta- tions of the ABL gene.
💡
Conclusion & Impact:Analyzing the mutations and monitor- ing (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become a valuable tool for regular testing of patients in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Despite the efficacy of the BCR-ABL tyrosine kinase inhibitor imatinib, the development of resistance against imatinib has been observed. The most important mechanisms known to cause resistance are point mutations in the ABL tyrosine kinase and the ATP domain. This study describes the use of denaturing high performance liquid chromatography (dHPLC) as a method to screen for muta- tions of the ABL gene. Material and Methods: We used the dHPLC based assay for the screening of ABL point mutations. Forty chronic myeloid leukemia (CML) patients who showed resistance to imatinib were screened in parallel by dHPLC and direct sequencing. Results: Nine of the 40 patients (23%) had mutations. Conclusion: dHPLC can be a useful method for pre-screening. Analyzing the mutations and monitor- ing (high-risk) patients can improve their prognosis and survival rate. dHPLC can potentially become a valuable tool for regular testing of patients in the future.

Özet

Amaç: Bir BCR-ABL tirozin kinaz inhibitörü olan imatinibin etkinliğine karşın bazı hastalarda ilaca karşı direnç gelişimi gözlenmektedir.. Direnç gelişimine neden olan en önemli mekanizma, ABL geninin tirozin kinaz ve ATP bölgelerindeki nokta mutasyonlarıdır. Bu çalışma ABL gen mutasyonlarının taranmasında denatüre edici HPLC (dHPLC) yönteminin yerini ve önemini açıklama amacıyla yapılmıştır. Yöntemler ve Gereçler: ABL nokta mutasyonları, dHPLC kullanılarak taranmıştır. Imatinib direnci gösteren 40 KML hastası DHPLC ve paralelinde doğrudan sekanslama ile incelenmiştir. Bulgular: Kırk hastanın dokuzunda (%23) mutasyon saptandı. Sonuç: dHPLC yararlı bir ön tarama yöntemi olabilir. Mutasyon analizleri ile yüksek riskli hastaların monitörizasyonu prognozu iyileştirebilir ve sağ kalım oranını arttırabilir. Gelecekte dHPLC bu hastaların düzenli aralıklarla izleminde değerli bir araç olarak kullanılabilir.

🔖

Cite This Article

ERBİLGİN, Y., ÇATAL, S., EŞKAZAN, A. E., NG, Ö. H., SOYSAL, T., ÖZBEK, U. (2011). Denatüre edici yüksek performanslı likit kromotografi yöntemi ile ABL geni kinaz bölgesi mutasyonlarının taranması. Turkish Journal of Hematology, Cilt: 28 - Sayı: 2, 97–102. https://ajindex.com/articles/413339

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identi- fied by quinacrine fluorescence and Giemsa staining. Nature 1973
  2. [CrossRef] 2.National Comprehensive Cancer Network (2008). Chronic myelogenous leukemia V.I.2008. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/ professionalsphysician_gls/PDF/cml.pdf. Accessed 19 September 2008. 3.Griffin JD, Todd RF 3rd, Ritz J, Nadler LM, Canellos GP Rosenthal D, Gallivan M, Beveridge RP Weinstein H, Karp D, Schlossman SF. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood 1983
  3. Bettelheim P Lutz D, Majdic O, Paietta E, Haas O, Linkesch W, Neumann E, Lechner K, Knapp W. Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Hematol 1985
  4. European LeukemiaNet (2008) Management of chron- ic myeloid leukemia (CML): recommendations from the European LeukemiaNet (ELN). http://www.leuke- mia-net.org/content/leukemias/cml/standards_sops/ recommendations/. Accessed 2 Sept 2008. 6.Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson- Smith MA, Davies T, Stone M, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leu- kaemia. Nature 1983
  5. 306277-80. [CrossRef] 7.Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984
  6. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996
  7. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000
  8. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002
  9. [CrossRef] 11.Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E
  10. International STI571 CML Study Group. Efficacy and safety of a specific inhibitor of the BCR- ABL tyrosine kinase in chronic myel